Daiwa Capital Markets lowered shares of Takeda Pharmaceutical (NYSE:TAK) from an outperform rating to a neutral rating in a research report released on Thursday morning, Briefing.com Automated Import reports.
A number of other research firms have also recently weighed in on TAK. Zacks Investment Research cut shares of Takeda Pharmaceutical from a buy rating to a hold rating in a report on Wednesday, August 7th. ValuEngine cut shares of Takeda Pharmaceutical from a hold rating to a sell rating in a report on Wednesday, May 15th.
TAK stock opened at $16.72 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. Takeda Pharmaceutical has a fifty-two week low of $15.50 and a fifty-two week high of $21.95. The business has a 50-day moving average price of $17.52. The firm has a market cap of $26.34 billion, a PE ratio of 32.78 and a beta of 0.69.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Article: How does the Beige Book influence monetary policy?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.